The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2George W. Sledge, Antonio Llombart‐Cussac, PierFranco Conte et al.|JAMA Oncology|2019Cited by 983
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancerStephen Johnston, Matthew P. Goetz|npj Breast Cancer|2019Cited by 673
Assessment of Molecular Relapse Detection in Early-Stage Breast CancerIsaac García-Murillas, Nicholas C. Turner, Neha Chopra et al.|JAMA Oncology|2019Cited by 425
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.Mitch Dowsett, Ian E. Smith, Alison Jones et al.|PubMed|1995Cited by 239
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET TrialStephen Johnston, Samuel A. Jacobs, Shannon Puhalla et al.|Journal of Clinical Oncology|2018Cited by 233